Roferon-A in chronic viral hepatitis: treatment, clinical outcomes, cost-effectiveness
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Bern u.a.
Lang
1994
|
| Schriftenreihe: | Gesundheit und Ökonomie
6 |
| Schlagworte: | |
| Beschreibung: | 115 S. graph. Darst. |
| ISBN: | 3906752666 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV009594430 | ||
| 003 | DE-604 | ||
| 005 | 19950209 | ||
| 007 | t | ||
| 008 | 940509s1994 gw d||| |||| 00||| eng d | ||
| 016 | 7 | |a 940952891 |2 DE-101 | |
| 020 | |a 3906752666 |9 3-906752-66-6 | ||
| 035 | |a (OCoLC)31819399 | ||
| 035 | |a (DE-599)BVBBV009594430 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-12 |a DE-703 | ||
| 050 | 0 | |a RC848.H43 | |
| 082 | 0 | |a 616.3/62301 |2 20 | |
| 084 | |a QX 700 |0 (DE-625)142186: |2 rvk | ||
| 100 | 1 | |a Schwicker, David |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Roferon-A in chronic viral hepatitis |b treatment, clinical outcomes, cost-effectiveness |c David Schwicker ; Kurt Banz |
| 264 | 1 | |a Bern u.a. |b Lang |c 1994 | |
| 300 | |a 115 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Gesundheit und Ökonomie |v 6 | |
| 650 | 4 | |a Cost-Benefit Analysis | |
| 650 | 4 | |a Hepatitis, Chronic |x drug therapy | |
| 650 | 4 | |a Hepatitis, Chronic |x economics | |
| 650 | 4 | |a Hepatitis, Viral | |
| 650 | 4 | |a Hepatitis, Viral, Human |x drug therapy | |
| 650 | 4 | |a Hepatitis, Viral, Human |x economics | |
| 650 | 4 | |a Interferon Alfa-2a |x economics | |
| 650 | 4 | |a Interferon Alfa-2a |x therapeutic use | |
| 650 | 4 | |a Outcome Assessment (Health Care) | |
| 650 | 0 | 7 | |a Kosten-Nutzen-Analyse |0 (DE-588)4032589-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Hepatitis B |0 (DE-588)4159548-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Hepatitis C |0 (DE-588)4262007-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Interferon |g alpha- |0 (DE-588)4205303-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krankheitskosten |0 (DE-588)4247917-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Virushepatitis |0 (DE-588)4290453-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Interferon |g alpha-2a- |0 (DE-588)4353085-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapieerfolg |0 (DE-588)4126073-9 |2 gnd |9 rswk-swf |
| 651 | 7 | |a Deutschland |0 (DE-588)4011882-4 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a Hepatitis B |0 (DE-588)4159548-8 |D s |
| 689 | 0 | 1 | |a Interferon |g alpha- |0 (DE-588)4205303-1 |D s |
| 689 | 0 | 2 | |a Therapieerfolg |0 (DE-588)4126073-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Hepatitis B |0 (DE-588)4159548-8 |D s |
| 689 | 1 | 1 | |a Interferon |g alpha- |0 (DE-588)4205303-1 |D s |
| 689 | 1 | 2 | |a Kosten-Nutzen-Analyse |0 (DE-588)4032589-1 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Hepatitis C |0 (DE-588)4262007-7 |D s |
| 689 | 2 | 1 | |a Interferon |g alpha- |0 (DE-588)4205303-1 |D s |
| 689 | 2 | 2 | |a Therapieerfolg |0 (DE-588)4126073-9 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Hepatitis C |0 (DE-588)4262007-7 |D s |
| 689 | 3 | 1 | |a Interferon |g alpha- |0 (DE-588)4205303-1 |D s |
| 689 | 3 | 2 | |a Kosten-Nutzen-Analyse |0 (DE-588)4032589-1 |D s |
| 689 | 3 | |5 DE-604 | |
| 689 | 4 | 0 | |a Deutschland |0 (DE-588)4011882-4 |D g |
| 689 | 4 | 1 | |a Virushepatitis |0 (DE-588)4290453-5 |D s |
| 689 | 4 | 2 | |a Interferon |g alpha-2a- |0 (DE-588)4353085-0 |D s |
| 689 | 4 | 3 | |a Krankheitskosten |0 (DE-588)4247917-4 |D s |
| 689 | 4 | |5 DE-604 | |
| 700 | 1 | |a Banz, Kurt |e Verfasser |4 aut | |
| 830 | 0 | |a Gesundheit und Ökonomie |v 6 |w (DE-604)BV000808167 |9 6 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-006342269 | ||
Datensatz im Suchindex
| _version_ | 1804123937047576576 |
|---|---|
| any_adam_object | |
| author | Schwicker, David Banz, Kurt |
| author_facet | Schwicker, David Banz, Kurt |
| author_role | aut aut |
| author_sort | Schwicker, David |
| author_variant | d s ds k b kb |
| building | Verbundindex |
| bvnumber | BV009594430 |
| callnumber-first | R - Medicine |
| callnumber-label | RC848 |
| callnumber-raw | RC848.H43 |
| callnumber-search | RC848.H43 |
| callnumber-sort | RC 3848 H43 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | QX 700 |
| ctrlnum | (OCoLC)31819399 (DE-599)BVBBV009594430 |
| dewey-full | 616.3/62301 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.3/62301 |
| dewey-search | 616.3/62301 |
| dewey-sort | 3616.3 562301 |
| dewey-tens | 610 - Medicine and health |
| discipline | Wirtschaftswissenschaften Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03081nam a2200817 cb4500</leader><controlfield tag="001">BV009594430</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19950209 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">940509s1994 gw d||| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">940952891</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3906752666</subfield><subfield code="9">3-906752-66-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)31819399</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009594430</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-703</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC848.H43</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.3/62301</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QX 700</subfield><subfield code="0">(DE-625)142186:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schwicker, David</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Roferon-A in chronic viral hepatitis</subfield><subfield code="b">treatment, clinical outcomes, cost-effectiveness</subfield><subfield code="c">David Schwicker ; Kurt Banz</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bern u.a.</subfield><subfield code="b">Lang</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">115 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Gesundheit und Ökonomie</subfield><subfield code="v">6</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cost-Benefit Analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis, Chronic</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis, Chronic</subfield><subfield code="x">economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis, Viral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis, Viral, Human</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis, Viral, Human</subfield><subfield code="x">economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interferon Alfa-2a</subfield><subfield code="x">economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interferon Alfa-2a</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Outcome Assessment (Health Care)</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kosten-Nutzen-Analyse</subfield><subfield code="0">(DE-588)4032589-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hepatitis B</subfield><subfield code="0">(DE-588)4159548-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hepatitis C</subfield><subfield code="0">(DE-588)4262007-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Interferon</subfield><subfield code="g">alpha-</subfield><subfield code="0">(DE-588)4205303-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krankheitskosten</subfield><subfield code="0">(DE-588)4247917-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Virushepatitis</subfield><subfield code="0">(DE-588)4290453-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Interferon</subfield><subfield code="g">alpha-2a-</subfield><subfield code="0">(DE-588)4353085-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapieerfolg</subfield><subfield code="0">(DE-588)4126073-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Deutschland</subfield><subfield code="0">(DE-588)4011882-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Hepatitis B</subfield><subfield code="0">(DE-588)4159548-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Interferon</subfield><subfield code="g">alpha-</subfield><subfield code="0">(DE-588)4205303-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Therapieerfolg</subfield><subfield code="0">(DE-588)4126073-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Hepatitis B</subfield><subfield code="0">(DE-588)4159548-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Interferon</subfield><subfield code="g">alpha-</subfield><subfield code="0">(DE-588)4205303-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Kosten-Nutzen-Analyse</subfield><subfield code="0">(DE-588)4032589-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Hepatitis C</subfield><subfield code="0">(DE-588)4262007-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Interferon</subfield><subfield code="g">alpha-</subfield><subfield code="0">(DE-588)4205303-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Therapieerfolg</subfield><subfield code="0">(DE-588)4126073-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Hepatitis C</subfield><subfield code="0">(DE-588)4262007-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Interferon</subfield><subfield code="g">alpha-</subfield><subfield code="0">(DE-588)4205303-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="2"><subfield code="a">Kosten-Nutzen-Analyse</subfield><subfield code="0">(DE-588)4032589-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="4" ind2="0"><subfield code="a">Deutschland</subfield><subfield code="0">(DE-588)4011882-4</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="4" ind2="1"><subfield code="a">Virushepatitis</subfield><subfield code="0">(DE-588)4290453-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="2"><subfield code="a">Interferon</subfield><subfield code="g">alpha-2a-</subfield><subfield code="0">(DE-588)4353085-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="3"><subfield code="a">Krankheitskosten</subfield><subfield code="0">(DE-588)4247917-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Banz, Kurt</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Gesundheit und Ökonomie</subfield><subfield code="v">6</subfield><subfield code="w">(DE-604)BV000808167</subfield><subfield code="9">6</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006342269</subfield></datafield></record></collection> |
| geographic | Deutschland (DE-588)4011882-4 gnd |
| geographic_facet | Deutschland |
| id | DE-604.BV009594430 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:37:42Z |
| institution | BVB |
| isbn | 3906752666 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006342269 |
| oclc_num | 31819399 |
| open_access_boolean | |
| owner | DE-12 DE-703 |
| owner_facet | DE-12 DE-703 |
| physical | 115 S. graph. Darst. |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Lang |
| record_format | marc |
| series | Gesundheit und Ökonomie |
| series2 | Gesundheit und Ökonomie |
| spelling | Schwicker, David Verfasser aut Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness David Schwicker ; Kurt Banz Bern u.a. Lang 1994 115 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Gesundheit und Ökonomie 6 Cost-Benefit Analysis Hepatitis, Chronic drug therapy Hepatitis, Chronic economics Hepatitis, Viral Hepatitis, Viral, Human drug therapy Hepatitis, Viral, Human economics Interferon Alfa-2a economics Interferon Alfa-2a therapeutic use Outcome Assessment (Health Care) Kosten-Nutzen-Analyse (DE-588)4032589-1 gnd rswk-swf Hepatitis B (DE-588)4159548-8 gnd rswk-swf Hepatitis C (DE-588)4262007-7 gnd rswk-swf Interferon alpha- (DE-588)4205303-1 gnd rswk-swf Krankheitskosten (DE-588)4247917-4 gnd rswk-swf Virushepatitis (DE-588)4290453-5 gnd rswk-swf Interferon alpha-2a- (DE-588)4353085-0 gnd rswk-swf Therapieerfolg (DE-588)4126073-9 gnd rswk-swf Deutschland (DE-588)4011882-4 gnd rswk-swf Hepatitis B (DE-588)4159548-8 s Interferon alpha- (DE-588)4205303-1 s Therapieerfolg (DE-588)4126073-9 s DE-604 Kosten-Nutzen-Analyse (DE-588)4032589-1 s Hepatitis C (DE-588)4262007-7 s Deutschland (DE-588)4011882-4 g Virushepatitis (DE-588)4290453-5 s Interferon alpha-2a- (DE-588)4353085-0 s Krankheitskosten (DE-588)4247917-4 s Banz, Kurt Verfasser aut Gesundheit und Ökonomie 6 (DE-604)BV000808167 6 |
| spellingShingle | Schwicker, David Banz, Kurt Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness Gesundheit und Ökonomie Cost-Benefit Analysis Hepatitis, Chronic drug therapy Hepatitis, Chronic economics Hepatitis, Viral Hepatitis, Viral, Human drug therapy Hepatitis, Viral, Human economics Interferon Alfa-2a economics Interferon Alfa-2a therapeutic use Outcome Assessment (Health Care) Kosten-Nutzen-Analyse (DE-588)4032589-1 gnd Hepatitis B (DE-588)4159548-8 gnd Hepatitis C (DE-588)4262007-7 gnd Interferon alpha- (DE-588)4205303-1 gnd Krankheitskosten (DE-588)4247917-4 gnd Virushepatitis (DE-588)4290453-5 gnd Interferon alpha-2a- (DE-588)4353085-0 gnd Therapieerfolg (DE-588)4126073-9 gnd |
| subject_GND | (DE-588)4032589-1 (DE-588)4159548-8 (DE-588)4262007-7 (DE-588)4205303-1 (DE-588)4247917-4 (DE-588)4290453-5 (DE-588)4353085-0 (DE-588)4126073-9 (DE-588)4011882-4 |
| title | Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness |
| title_auth | Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness |
| title_exact_search | Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness |
| title_full | Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness David Schwicker ; Kurt Banz |
| title_fullStr | Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness David Schwicker ; Kurt Banz |
| title_full_unstemmed | Roferon-A in chronic viral hepatitis treatment, clinical outcomes, cost-effectiveness David Schwicker ; Kurt Banz |
| title_short | Roferon-A in chronic viral hepatitis |
| title_sort | roferon a in chronic viral hepatitis treatment clinical outcomes cost effectiveness |
| title_sub | treatment, clinical outcomes, cost-effectiveness |
| topic | Cost-Benefit Analysis Hepatitis, Chronic drug therapy Hepatitis, Chronic economics Hepatitis, Viral Hepatitis, Viral, Human drug therapy Hepatitis, Viral, Human economics Interferon Alfa-2a economics Interferon Alfa-2a therapeutic use Outcome Assessment (Health Care) Kosten-Nutzen-Analyse (DE-588)4032589-1 gnd Hepatitis B (DE-588)4159548-8 gnd Hepatitis C (DE-588)4262007-7 gnd Interferon alpha- (DE-588)4205303-1 gnd Krankheitskosten (DE-588)4247917-4 gnd Virushepatitis (DE-588)4290453-5 gnd Interferon alpha-2a- (DE-588)4353085-0 gnd Therapieerfolg (DE-588)4126073-9 gnd |
| topic_facet | Cost-Benefit Analysis Hepatitis, Chronic drug therapy Hepatitis, Chronic economics Hepatitis, Viral Hepatitis, Viral, Human drug therapy Hepatitis, Viral, Human economics Interferon Alfa-2a economics Interferon Alfa-2a therapeutic use Outcome Assessment (Health Care) Kosten-Nutzen-Analyse Hepatitis B Hepatitis C Interferon alpha- Krankheitskosten Virushepatitis Interferon alpha-2a- Therapieerfolg Deutschland |
| volume_link | (DE-604)BV000808167 |
| work_keys_str_mv | AT schwickerdavid roferonainchronicviralhepatitistreatmentclinicaloutcomescosteffectiveness AT banzkurt roferonainchronicviralhepatitistreatmentclinicaloutcomescosteffectiveness |